dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Quintela-Fandino, Miguel |
dc.contributor.author | Holgado, Esther |
dc.contributor.author | Manso, Luis |
dc.contributor.author | Bermejo, Begoña |
dc.contributor.author | Colomer, Ramon |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Morales, Serafin |
dc.date.accessioned | 2021-09-10T10:07:06Z |
dc.date.available | 2021-09-10T10:07:06Z |
dc.date.issued | 2020-11-11 |
dc.identifier.citation | Quintela-Fandino M, Holgado E, Manso L, Morales S, Bermejo B, Colomer R, et al. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Res. 2020 Nov 11;22:124. |
dc.identifier.issn | 1465-542X |
dc.identifier.uri | https://hdl.handle.net/11351/6299 |
dc.description | Bevacizumab; Durvalumab; Càncer de mama HER2 negatiu |
dc.description.sponsorship | MQF is a recipient of the following grants: AES - PI16/00354 funded by the ISCIII and co-funded by the European Regional Development Fund (ERDF) and B2017/BMD3733 (Immunothercan-CM) - Call for Coordinated Research Groups from Madrid Region - Madrid Regional Government - ERDF funds. SM is a recipient of the following grants: Spanish Ministerio de Economía y Competitividad (MINECO) (SAF2017-83732-R; AEI/FEDER, EU) and co-funded by Comunidad de Madrid (B2017/BMD3733; Immunothercan-CM). RC is a recipient RC is a recipient of the ISCIII grants PIE15/00068 and PI17/01865. The study was also funded by CRIS Contra el Cancer Foundation and Astra Zeneca Spain. Astra Zeneca Spain provided durvalumab. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Breast Cancer Research;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer |
dc.subject | Medicaments antineoplàstics - Ús terapèutic |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13058-020-01362-y |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1186/s13058-020-01362-y |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Quintela-Fandino M] Breast Cancer Clinical Research Unit – Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain. Medical Oncology Department, Hospital Universitario de Fuenlabrada, Fuenlabrada, Spain. Medical Oncology Department, Hospital Universitario Quiron, Pozuelo de Alarcon, Spain. [Holgado E] Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain. [Manso L] Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain. [Morales S] Medical Oncology Department, Hospital Universitari Arnau Vilanova, Lleida, Spain. [Bermejo B] Medical Oncology Department, Hospital Clínico Universitario, Valencia, Spain. INCLIVA, Valencia, Spain. CIBERONC, Instituto Carlos III, Madrid, Spain. [Colomer R] Breast Cancer Clinical Research Unit – Clinical Research Program, CNIO - Spanish National Cancer Research Center, Melchor Fernandez Almagro, 3, 28029 Madrid, Spain. Medical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain. Facultad de Medicina, Universidad Autónoma de Madrid, Madrid, Spain. [Cortes J] ION Institute of Oncology, Quironsalud Group – Madrid & Barcelona, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33176887 |
dc.identifier.wos | 000590839300002 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00354 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/SAF2017-83732-R |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PIE15%2F00068 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F01865 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |